Target intelligence / Profile preview

Cystic fibrosis transmembrane conductance regulator (CFTR) mRNA with premature termination codons (CFTR mRNA (PTC))

Target
CFTR mRNA (PTC)
Molecular classification
Other, Messenger RNA, Nucleic acid
01

Overview

Cystic fibrosis transmembrane conductance regulator (CFTR) mRNA containing premature termination codons (PTCs) is the primary driver of Class I cystic fibrosis mutations. These nonsense mutations, such as G542X or W1282X, introduce a stop signal prematurely in the genetic sequence, leading to the production of truncated, non-functional proteins (Cystic Fibrosis Foundation). Furthermore, these PTC-containing transcripts are frequently targeted for degradation by the cellular nonsense-mediated mRNA decay (NMD) pathway, which significantly reduces the pool of available mRNA for translation (Linde & Kerem, 2008). This target is unique because therapeutic intervention occurs during the translation process, where small molecules called read-through agents interact with the ribosome. These agents, such as Ataluren or ELX-02, facilitate the bypass of the premature stop signal by promoting the insertion of a near-cognate amino acid at the PTC site (Welch et al., 2007). This process allows the ribosome to continue translation to the natural stop codon, resulting in the synthesis of full-length, functional CFTR protein. Current research also explores the use of NMD inhibitors to stabilize the mRNA, thereby increasing the substrate available for read-through therapy (Sharma et al., 2021). Restoring CFTR function at the cell membrane is essential for normalizing chloride and bicarbonate transport, which alleviates the thick mucus accumulation in the lungs and other organs. Clinical monitoring of this target often involves measuring sweat chloride levels or nasal potential difference to assess the restoration of ion channel activity. Despite challenges such as low read-through efficiency and potential off-target effects, targeting CFTR mRNA remains a critical strategy for treating patients with nonsense mutations who do not benefit from standard CFTR modulators.

Other names
PTC-containing CFTR mRNACFTR mRNA with nonsense mutationsNonsense-mutated CFTR mRNAPremature stop codon CFTR mRNA
02

Mechanism of action

Induction of translational read-through at premature termination codons and inhibition of nonsense-mediated mRNA decay (NMD) (Welch et al., 2007; Sharma et al., 2021).

03

Biological functions

OtherTemplate for protein synthesisRegulation of ion transportGenetic information carrier
04

Disease associations

OtherCystic FibrosisGenetic disease
05

Safety considerations

Aminoglycoside-induced ototoxicityNephrotoxicityPotential for global read-through of natural stop codonsLow clinical efficacy due to NMD-mediated transcript depletion
06

Interacting drugs

Ataluren

4 more in the full profile.

07

Biomarkers

Sweat chloride concentrationNasal potential difference (NPD)CFTR mRNA expression levelsG542X genotypeW1282X genotype

Beyond the preview

Go deeper on Cystic fibrosis transmembrane conductance regulator (CFTR) mRNA with premature termination codons (CFTR mRNA (PTC)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cystic fibrosis transmembrane conductance regulator (CFTR) mRNA with premature termination codons (CFTR mRNA (PTC)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call